Orelabrutinib shows promising results in reducing RRMS brain lesions.
Originally Published 2 years ago — by Multiple Sclerosis News Today
InnoCare Pharma's orelabrutinib, an experimental inhibitor of the Bruton's tyrosine kinase (BTK) enzyme, has shown significant reductions in new active brain lesions among people with relapsing-remitting multiple sclerosis (RRMS) in a 12-week interim analysis of a global Phase 2 trial. The trial has met its main goal, overall "supporting further development" of orelabrutinib for MS. Orelabrutinib is expected to ease inflammation and slow MS progression by preventing the activation of immune cell populations implicated in MS, namely B-cells and macrophages.